Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03451578 · ClinicalTrials.gov registry record · NA
Alpha MSH in Ocular Disease
A NA study, sponsored by Duke University.
- Completed
- Registry status
- NA
- Development phase
- 54
- Enrollment target
NCT03451578 is a NA study that has completed, run by Duke University. The registered enrollment target is 54 participants.
The verdict
NCT03451578, a NA study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- NA
- Development phase
- 54 participants
- Enrollment target
Study Summary
The purpose of this study is gain a better understanding of a molecule called alpha melanocyte stimulating hormone (alpha MSH) and its potential role in your retinal disease. Alpha MSH has been shown to have an important role in the regulation of ocular immunity in animal models of inflammatory retinal diseases and retinal dystrophies, and there may be a protective effect of alpha MSH. By studying the levels of alpha MSH in your eye we may better understand its role in advanced dry macular degeneration. By studying the levels of this molecule we hope to better understand if it may be a good target for future treatment.
Interventions
- DEVICE Alpha MSH assay
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2018-03-06 |
| Est. Completion | 2021-10-19 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03451578
The ClinicalTrials.gov registry entry for NCT03451578 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Alpha MSH assay is the first listed.
NCT03451578 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03451578 about?
NCT03451578 is a clinical study titled "Alpha MSH in Ocular Disease". The purpose of this study is gain a better understanding of a molecule called alpha melanocyte stimulating hormone (alpha MSH) and its potential role in your retinal disease. Alpha MSH has been shown to have an important role in the regulation of ocular immunity in animal models of inflammatory reti...
What is the current status of trial NCT03451578?
This trial is currently completed. It is a NA study. The enrollment target is 54 participants. The study started on 2018-03-06. Estimated completion is 2021-10-19.
What interventions are being tested in trial NCT03451578?
The interventions under investigation include: Alpha MSH assay (DEVICE).
Who is sponsoring clinical trial NCT03451578?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.